Results from two large, phase III studies (HAWK and HARRIER) have found brolucizumab 6 mg (Novartis) produced better anatomical outcomes than aflibercept-in terms of retinal thickness, intraretinal fluid (IRF), and/or subretinal fluid (SR
AMD Nurturing Program
Endophthalmitis may be a rare occurrence, but it can be a devastating one. Acute cases are known to be caused by gram-positive bacteria and usually present within 6 weeks post-surgery.
A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Age-related macular degeneration (AMD) is the leading cause of significant visual acuity loss in people over the age of 50 in developed countries. Almost 80% of the people diagnosed with AMD will have the non-neovascular (dry) or atrophic subtypes. Here is the clinical information patients need to understand this disease.
The American Academy of Ophthalmology’s Preferred Practice Pattern on Age-Related Macular Degeneration “are based on the best available scientific data as interpreted by panels of knowledgeable health professionals.” These patterns offer solid clinical guidelines for treating and counseling AMD patients.
Two of the top 10 “most-talked-about” articles in JAMA Ophthalmology are about age-related macular degeneration (AMD). One of the current top 5 “most-read” articles in the American Journal of Ophthalmology is also about AMD. Here are a brief synopsis of those three papers.
A low dose of ranibizumab (Lucentis, Genentech/Roche) works well as a treatment for retinopathy of prematurity (ROP), researchers say.
Topline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
A new high-density OCT angiography system (AngioVueHD, OptoVue) provides exquisite views of the retinal microvasculature without the need for injection of fluorescein dye.
The importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.